Pfizer Ventures is the largest individual shareholder in the cancer therapeutics developer, which has filed for a $100m offering.

US-based cancer drug developer BioAtla has filed to raise up to $100m in an initial public offering that would represent an exit for pharmaceutical firm Pfizer. BioAtla is developing conditionally active biologics (CABs) to treat solid tumours, and its therapeutics are designed to differentiate between the tumour microenvironment and healthy tissue through characteristic differences in…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.